Consistent with Robbie Carson et al., who verified that HDAC inhibitors combined with MEK inhibitors could effectively overcome resistance to MEK inhibition in BRAF-mutant colorectal cancer [41], we found that knockout and pharmacological inhibition of HDAC2 combined with sorafenib could reverse sorafenib resistance. The gene discussed is BRAF; the disease is colorectal cancer.